Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| MRNA | Moderna, Inc. | -5.15% | 122.98 | 0.0% | $2605.58m | |
| BNGO | BioNano Genomics, Inc. | 13.29% | 9.55 | 0.0% | $1909.26m | |
| GILD | Gilead Sciences, Inc. | 6.66% | 67.55 | 1.0% | $668.56m | |
| CRSP | CRISPR Therapeutics AG | -1.19% | 197.50 | 0.6% | $576.08m | |
| AMGN | Amgen, Inc. | 1.18% | 248.40 | 1.3% | $558.77m | |
| NVAX | Novavax, Inc. | 3.92% | 132.42 | 92.9% | $487.14m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 3.24% | 534.69 | 2.7% | $472.42m | |
| ALXN | Alexion Pharmaceuticals, Inc. | 1.31% | 158.75 | 2.0% | $463.44m | |
| ILMN | Illumina, Inc. | 1.56% | 382.24 | 3.5% | $364.85m | |
| BIIB | Biogen, Inc. | 1.20% | 279.16 | 1.7% | $339.01m | |
| VRTX | Vertex Pharmaceuticals, Inc. | 0.93% | 227.65 | 1.9% | $330.75m | |
| SRPT | Sarepta Therapeutics, Inc. | 3.28% | 93.28 | 13.8% | $328.90m | |
| OCGN | Ocugen, Inc. | 5.01% | 2.33 | 0.0% | $320.61m | |
| BNTX | BioNTech SE | 0.90% | 102.50 | 0.0% | $317.28m | |
| PACB | Pacific Biosciences of California, Inc. | 3.67% | 38.28 | 7.4% | $264.84m |
Company Profile
Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA.